Pancrelipase Capsules
ApprovedRecruiting 0 watching 0 views this week🔥 Hot
85
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Exocrine Pancreatic Insufficiency
Conditions
Exocrine Pancreatic Insufficiency
Trial Timeline
Feb 1, 2024 → Jul 31, 2027
NCT ID
NCT06477159About Pancrelipase Capsules
Pancrelipase Capsules is a approved stage product being developed by AbbVie for Exocrine Pancreatic Insufficiency. The current trial status is recruiting. This product is registered under clinical trial identifier NCT06477159. Target conditions include Exocrine Pancreatic Insufficiency.
Hype Score Breakdown
Clinical
30
Activity
20
Company
10
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT06477159 | Approved | Recruiting |
Competing Products
6 competing products in Exocrine Pancreatic Insufficiency
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Pancrelipase in combination with Ensure Plus | Johnson & Johnson | Phase 1 | 33 |
| Pancrease MT 10.5, or MT 21 + Placebo for Pancrease MT 10.5 or MT 21 | Johnson & Johnson | Phase 3 | 77 |
| CREON | AbbVie | Approved | 85 |
| Creon IR + Creon® (DR/GR) | AbbVie | Phase 2 | 52 |
| Pancrelipase + Placebo | AbbVie | Approved | 85 |
| Lipacreon | Viatris | Pre-clinical | 20 |